Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells
Authors:
- Yong YangYYYong Yang
- Na LuNLNa Lu
- Qi-Dong YouQYQi-Dong You
- Sen WangSWSen Wang
- Ying GaoYGYing Gao
- Yan ChenYCYan Chen
- Qing-Long GuoQGQing-Long Guo
- 1 September 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 361 (1) , 79-84
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antiangiogenesis in cancer therapy—endostatin and its mechanisms of actionExperimental Cell Research, 2006
- Endogenous angiogenesis inhibitorsAPMIS, 2004
- Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated DailyJournal of Clinical Oncology, 2002
- Interaction of endostatin with integrins implicated in angiogenesisProceedings of the National Academy of Sciences, 2001
- Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangiesFrontiers in Bioscience-Landmark, 2001
- Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc bindingThe EMBO Journal, 1999
- Cloning, Expression, andin VitroActivity of Human EndostatinBiochemical and Biophysical Research Communications, 1999
- Endostatin Induces Endothelial Cell ApoptosisJournal of Biological Chemistry, 1999
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971